Drug Profile
Research programme: neurological disorder therapeutics - NeuroRepair
Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator NeuroRepair; University of California at Irvine
- Class Antineoplastics; Antiulcers; Antivirals; Growth factors; Transforming growth factors
- Mechanism of Action Transforming growth factor alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Parkinson's disease; Stroke
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Parkinson's disease in USA (Parenteral)
- 12 Sep 2023 Discontinued - Preclinical for Stroke in USA (Parenteral)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (Parenteral)